Dyne Therapeutics Q2 2024 GAAP EPS $(0.70) Beats $(0.72) Estimate
Portfolio Pulse from Benzinga Newsdesk
Dyne Therapeutics (NASDAQ:DYN) reported a Q2 2024 GAAP EPS of $(0.70), beating the analyst consensus estimate of $(0.72) by 2.78%. This represents a 35.19% improvement over the losses of $(1.08) per share from the same period last year.
August 12, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyne Therapeutics reported a Q2 2024 GAAP EPS of $(0.70), beating the analyst consensus estimate of $(0.72) and showing a significant improvement over the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100